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Abstract
Neuroendocrine tumours (NET) are a heterogeneous group of neoplasms commonly occurring in the gastrointestinal tract or lungs but 
can occur in other regions. Primary ovarian NET account for 5% of all NET and 0.1% of all ovarian malignancies. In metastatic disease, 
the therapeutic goal is to extend survival and to improve quality of life. As these tumours express somatostatin receptors, somatostatin 
analogues are frequently used to control symptoms. Here we present a case of a pregnant woman with an ovarian NET with liver metas-
tases and carcinoid syndrome who was treated with the somatostatin analogue, Octreotide LAR. We also summarize reported data of the 
use of somatostatin analogues during pregnancy.
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Introduction and background
Neuroendocrine tumours (NET) are a heterogeneous group of neoplasms commonly located in the gastrointestinal tract or lungs. Their 
incidence is less than five cases/100.000 per year and it has been increasing over the last three decades [1,2]. Primary ovarian NET 
account for 5% of NET and 0.1% of all ovarian malignancies [3].Five years overall survival is not well established, but exceeds 70% in 
some series.
Neuroendocrine cells secrete various hormones (serotonin, histamine, dopamine, substance P, neurotensin, prostaglandins) which are 
commonly inactivated by liver monoamine oxidases. Approximately 5% of patients affected by metastatic disease experiences carcinoid 
syndrome: cutaneous flushing, abdominal pain, diarrhoea and bronchospasm. Classical signs and symptoms usually occur when large 
liver metastases are present or when these amines pass directly into systemic circulation [4]. A carcinoid syndrome has been described in 
around 30% of ovarian carcinoids [5]. Either short- or long-acting somatostatin analogues (SSA) (Octreotide, Octreotide LAR, lanreotide) 
are routinely administered for preventing carcinoid syndrome and for inhibiting tumour growth [6,7]. Moreover, in last decade treatment 
with radioactive-labelled somatostatin analogues [90-Y-DOTATOC and 177LuDOTATATE] have been developed in order to improve symp-
toms of hormone hypersecretion and slow tumour growth [8,9].
Although the average age of carcinoid patients is 60 years, diagnosis can occur also during reproductive age [1,4]. Due to the changes in 
reproductive behaviour, with increased age at first and subsequent pregnancies and to the long-term survival of patients with NET, it is not 
exceptional that patients ask for advice about pregnancy or that they face unexpected pregnancies during treatments.
Few data on clinical and biological effects of SSA during pregnancy have been reported so far. In most cases, the drug is withdrawn before 
a planned pregnancy or immediately after its confirmation [10]. However, there are a number of published reports on pregnant acromegalic 
women, who received SSA either throughout the whole pregnancy or during part of it [11–13].
The clinical case
A nulliparous 31-year-old woman affected by ovarian NET with liver metastases and carcinoid syndrome was found to be 6 weeks preg-
nant by urine HCG test, while on Octreotide LAR 30 and 2 months after the 6th cycle of peptide receptor radionuclide therapy (PRRT) 
with 177Lu-DOTATATE ([177Lu-DOTA-Tyr3]-octreotate). The patients had regular menses during the previous year, and had not used con-
traceptive in the last 6 months.
Diagnosis of ovarian NET with liver metastases occurred 7 years earlier, when she started complaining of generalized flushing, diarrhoea 
and abdominal pain. In 2003, after a diagnostic laparotomy, she received six cycles of cisplatin and etoposide every 3 weeks with partial 
tumour regression, followed by Octreotide LAR (30 mg per month).
In September 2008, after hepatic and pelvic disease progression, she underwent right ovariectomy and peritoneal node dissection. 
Histological examination confirmed a NET involving the right ovary, with a proliferation index of 10% (Ki-67). Subsequently, she received 
PRRT with 177Lu-DOTATATE associated with intra muscular monthly Octreotide LAR. Three months after the sixth cycle of PRRT, (cumu-
lative activity dose 22.42 GBq – 606 mCi) (Figure 1A) an unplanned pregnancy was found. A dosimetric evaluation confirmed a very low 
risk of uterine irradiation (< 1 m Sv) at conception.
After onset of pregnancy, she experienced a significant worsening of symptoms, consisting of recurrent flushing, abdominal cramping, 
diarrhoea, severe orthostatic hypotension. No biochemical evaluation of vasoactive amines was performed. The patient was informed 
within a multi-disciplinary consultation about the possible maternal risks of continuing pregnancy and withdrawing SSA. The patient was 
also informed about the paucity of clinical data on the effects of Octreotide LAR on foetal integrity and growth. According to her desire to 
maintain the pregnancy, Octreotide LAR was stopped, oxatomide and ranitidine were started to limit symptoms associated with carcinoid 
syndrome and short-acting somatostatin analogue was suggested in case of worsening of maternal symptoms. However, spontaneous 
abortion occurred at 12th week of pregnancy, before any short-acting somatostatin analogue administration was attempted. Soon after 
miscarriage, the patient experienced a dramatic improvement in symptoms, with complete resolution of flushing.www.ecancer.org  3
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After uterine revision, which yielded endometrial tissue without any embryonic residual, PRRT was completed with two cycles of 177   
Lu-DOTATATE, achieving the total activity of 29.4 GBq (796 mCi) and Octreotide LAR was reintroduced with disease stabilization 
(Figure 1B). On her last clinical examination, 8 years after diagnosis, the patient, in good clinical condition, firmly expressed her desire to 
have a child in the next future, although she had concerns about the risk of symptoms worsening and flushing recurrence, as experienced 
in her previous gestation. Moreover, we discussed with her the new therapeutical strategies in order to further control the disease, as she 
has reached the maximum administrable activity of 177Lu-DOTATATE.
Discussion and conclusions
Generally, NET are slow-growing malignancies. Even when metastases occur, they often exhibit an indolent clinical course, with an overall 
5-year survival of 67%, across all stages and sites [1].Although the median age at diagnosis is usually in the sixth decade, they might 
Figure 1: Whole-body scan with 177Lu-DOTATATE performed 3 months before pregnancy and after the 6th cycle of PRRT (A) and after the 8th 
cycle of PRRT (B).ecancer 2012, 6:240
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occur also in young women, particularly when they involve the appendix or the ovary. Few anecdotal cases of NET in pregnancy have 
been reported in literature: most of them did not require treatment with somatostatin analogues, because of non-functioning tumours or 
because radical surgical resection was performed. Regarding the safety and feasibility of SSA in pregnancy, limited data are available, 
mainly on acromegalic patients (Table 1). Fassnacht and colleagues [11] reported the case of a young acromegalic woman who received 
Octreotide LAR throughout her pregnancy. RIA assessment of Octreotide in umbilical cord blood indicated a substantial materno-foetal 
circulation of the drug. Nevertheless, both placenta and foetus developed normally. Maffei and colleagues [13] described the case of 
an acromegalic woman treated with high dose of short-acting Octreotide throughout the whole pregnancy. A transient decrease in uter-
ine artery flow after Octreotide injections was detected, without effects on pregnancy and foetal development. Finally, Boulanger et al 
reported an uneventful pregnancy in a patient affected by pancreatic beta cell hyperplasia (nesidioblastosis) treated with Octreotide during 
the whole gestation[14].
Despite the expression of all five somatostatin receptors (SST1, SST2, SST3, SST4 and SST5) in human placenta of acromegalic and 
healthy women, a very low SSA binding to placenta and umbilical cord tissues has been observed. Previous in vitro and in vivo studies 
demonstrated that SSA bound with low affinity to human placental receptors and the absence of changes in human placental growth 
hormone (hPGH) and insulin growth factor-I (IGF-I) during Octreotide treatment in pregnancy [12]. Based on these findings, we told the 
patient that information about safety and feasibility of SSA during pregnancy were limited and suggested short-acting SSA, because this 
formulation is better manageable if any pregnancy complication occurs.
However, other aspects should be taken into account in pregnant women affected by functioning neuroendocrine tumours. Pregnancy 
induces an altered endocrinal milieu which could influence tumour progression, particularly when an endocrine responsive tumour is 
present. No data about NET progression during pregnancy have been reported (14, 20), but caution is mandatory. Our patient expe-
rienced an increase in carcinoid syndrome which significantly worsened during gestation. A similar finding was described by others in 
patients diagnosed with acromegaly or carcinoid syndrome during pregnancy [13,15]. Consistently high levels of vasoactive peptides have 
Authors Mother disease
Number of 
pregnancies Type of SSA dose
SSAs exposure period/
total week of exposure Delivery
Miscarriage/
complications
Cozzi R [10] Acromegaly 2/7 Lanreotide 1st trimester/4 weeks At term none
Fassnacht [11] Acromegaly 1 Octreotide LAR 10–20 mg Whole pregnancy 38th week Foetal growth 
retardation
Maffei [13] Acromegaly 1 Octreotide 100 µg/1–2 h 
(1200–2400 µg/24 h)
Whole pregnancy 38th week None
Le [15] Carcinoid 
syndrome
1 Octreotide LAR and 
Octreotide 25 µg/h iv 
during delivery
Partial gestation (unknown 
period) and delivery
37th week Mild foetal 
metabolic 
alkalemia
deMenis [18] Acromegaly 1 Lanreotide 30 mg 1st trimester/4 weeks 38th week None
Mikhail [19] Acromegaly 1 Octreotide 100 µg t.i.d. Whole pregnancy 38th week None
Mozas [20] Acromegaly 1 Octreotide 100 µg t.i.d. 1st and 2nd trimester/24 
weeks
ns None
Caron [21] TSH-
macroadenoma
1 Octreotide 300 µg die 
(continuous infusion)
1st and 3rd trimester/28 
weeks
8th month None
Boulanger [14] Nesidioblastosis 1 Octreotide 1000 µg in the 
first trimester
Whole pregnancy 32 weeks None
Table 1: Previously reported data of SSAs treatment while on pregnancywww.ecancer.org  5
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been associated with late onset cardiac lesions in 50–60% of patients with carcinoid syndrome [16]. 5-HIAA (5-hydroxyindolacetic acid) 
and serotonin levels correlate with the risk of developing right cardiac fibrosis and mitral valve stenosis. Somatostatin analogues are the 
mainstay of treatment in these cases. Thus, cardiac function and potential effects of SSA withdrawn should be accurately evaluated in 
pregnancy, also considering the cardiac load induced by pregnancy. Recently, the placental production of serotonin was described in 
pregnant women. Low maternal serotonin levels might influence foetal neurogenesis, including forebrain development, and were pos-
sibly related to mental disorders in adult offsprings[17]. A possible foetal neurotoxicity cannot be ruled out when SSA are administered 
during pregnancy, so this should be addressed during the counselling. Finally, functioning NET might create unexpected hemodynamic 
changes under anaesthesia. This condition, called carcinoid crisis is a life-threatening variant of carcinoid syndrome, characterized by 
severe hypotension (rarely hypertension) and bronchospasm. Therefore, an adequate planning of delivery in these patients is strongly 
recommended [15].
In conclusion, the opportunity of future conception could be considered in women with a history of syndromic NET, but all possible risks 
of getting pregnant should be critically discussed in details with the patient and a multi-disciplinary support should be offered both before 
and during pregnancy. Reproductive issues have become more frequent even in patients with rare tumors and caregivers should be ready 
to face these needs even without the support of solid evidences.
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